三氧化二砷抗肿瘤作用机制及其药物递送系统的研究进展

被引:17
作者
黄剑宇 [1 ,2 ]
梁启凡 [1 ,2 ]
李俊松 [1 ,2 ]
王若宁 [1 ,2 ]
狄留庆 [1 ,2 ]
机构
[1] 南京中医药大学药学院
[2] 江苏省中药高效给药系统工程技术研究中心
关键词
三氧化二砷; 抗肿瘤机制; 药物递送系统; 被动靶向; 主动靶向; 物理化学靶向; 细胞凋亡; 逆转耐药性; 抑制血管生成;
D O I
暂无
中图分类号
R285 [中药药理学];
学科分类号
100806 [中药药理学];
摘要
传统中药矿物药三氧化二砷具有显著的治疗作用,已被美国食品药品监督管理局(FDA)批准用于治疗急性早幼粒细胞白血病,近年来还发现其具有良好的治疗实体瘤的效果。其抗肿瘤机制主要包括促进细胞凋亡、抑制Hedgehog信号通路、逆转耐药性以及抑制血管生成等。然而三氧化二砷的体内靶向性较差、肾脏清除速率快、以及高剂量对正常组织的不良反应,限制了其对实体瘤的治疗应用与临床转化。新型药物递送系统在传统纳米制剂的基础上,提高了药物在肿瘤部位的聚集、控制释放以及诊断等能力,在精准治疗、提高生物利用度和降低毒副作用等方面具有重要意义。对三氧化二砷的抗肿瘤机制及抗肿瘤新型药物递送系统的研究进展进行总结和分析,以期为三氧化二砷抗肿瘤的深入研究和临床应用提供思路。
引用
收藏
页码:6102 / 6111
页数:10
相关论文
共 32 条
[1]
Effects of surface modification of As 2 O 3 -loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study.[J].Xiaoli Song;Juan You;Hongxia Shao;Caifeng Yan.Colloids and Surfaces B: Biointerfaces.2018,
[2]
Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells.[J].Nadra Sadaf;Nitish Kumar;Mehboob Ali;Vahab Ali;Sanjiva Bimal;Rizwanul Haque.Life Sciences.2018,
[3]
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.[J].Joachim Alexandre;Javid J. Moslehi;Kevin R. Bersell;Christian Funck-Brentano;Dan M. Roden;Joe-Elie Salem.Pharmacology and Therapeutics.2018,
[4]
Applications of stimuli-responsive nanoscale drug delivery systems in translational research [J].
Gu, Mengjie ;
Wang, Xin ;
Toh, Tan Boon ;
Chow, Edward Kai-Hua .
DRUG DISCOVERY TODAY, 2018, 23 (05) :1043-1052
[5]
Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors [J].
Drummond, Catherine J. ;
Hanna, Jason A. ;
Garcia, Matthew R. ;
Devine, Daniel J. ;
Heyrana, Alana J. ;
Finkelstein, David ;
Rehg, Jerold E. ;
Hatley, Mark E. .
CANCER CELL, 2018, 33 (01) :108-+
[6]
Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells [J].
Shi, Ying ;
Cao, Tong ;
Huang, Hua ;
Lian, Chaoqun ;
Yang, Ying ;
Wang, Zhiwei ;
Ma, Jia ;
Xia, Jun .
CELL CYCLE, 2017, 16 (24) :2396-2403
[7]
Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma [J].
Wadajkar, Aniket S. ;
Dancy, Jimena G. ;
Hersh, David S. ;
Anastasiadis, Pavlos ;
Tran, Nhan L. ;
Woodworth, Graeme F. ;
Winkles, Jeffrey A. ;
Kim, Anthony J. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2017, 9 (04)
[8]
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas [J].
Kumthekar, Priya ;
Grimm, Sean ;
Chandler, James ;
Mehta, Minesh ;
Marymont, Maryanne ;
Levy, Robert ;
Muro, Kenji ;
Helenowski, Irene ;
McCarthy, Katie ;
Fountas, Leanne ;
Raizer, Jeffrey .
JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (03) :589-594
[9]
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy.[J].Shu Yang;Huile Gao.Pharmacological Research.2017,
[10]
RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma [J].
Fei, Weidong ;
Zhang, Yan ;
Han, Shunping ;
Tao, Jiaoyang ;
Zheng, Hongyue ;
Wei, Yinghui ;
Zhu, Jiazhen ;
Li, Fanzhu ;
Wang, Xuanshen .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) :250-262